Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
2,5-Dimethyl-celecoxib
75
CHF
CHF 75.00
In stock
AG-CR1-3599-M0055 mgCHF 75.00
AG-CR1-3599-M02525 mgCHF 235.00
| Product Details | |
|---|---|
| Synonyms | DMC; 2,5-Dimethylcelecoxib |
| Product Type | Chemical |
| Properties | |
| Formula |
C18H16F3N3O2S |
| MW | 395.4 |
| CAS | 457639-26-8 |
| Purity Chemicals | ≥99% (HPLC) |
| Appearance | White solid. |
| Solubility | Soluble in DMSO, methanol or dichloromethane. |
| InChi Key | NTFOSUUWGCDXEF-UHFFFAOYSA-N |
| Smiles | CC1=CC=C(C)C(=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, that lacks COX-2 inhibitory function.
- Anti-proliferative, anti-tumorigenic and anti-angiogenic.
- Potent apoptosis inducer in many cancer cell lines.
- Down-regulates the expression of survivin, cyclins, MMPs and inhibits cyclin-dependent kinase activity.
- Modulates PDK-1, AKT, GSK3β, p70 S6K, PKA and MAPKAP-K1α.
- Reduces phosphorylation of ERK1/2 but not AKT T-308 or AKT S-473.
- Increases intracellular free calcium levels and potently triggers the endoplasmatic reticulum stress response (ESR), activating ER stress-associated proteins GRP78/BiP, CHOP/GADD153 and caspase-4.
Product References
- Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo: A. Kardosh, et al.; Cancer Biol. Ther. 4, 571 (2005)
- DMC: novel celecoxib derivatives to rap cancer: P. Dent, et al.; Cancer Biol. Ther. 4, 583 (2005)
- Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib: A. Kardosh, et al.; Blood 106, 4330 (2005)
- Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib: P. Pyrko, et al.; Mol. Cancer Ther. 6, 1262 (2007)
- Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib: A. Kardosh, et al.; Cancer Res. 68, 843 (2008)
- Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-κB: K. Deckmann, et al.; Biochem. Pharmacol. 80, 1365 (2010)
- Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature: J.J. Virrey, et al.; Mol. Cancer Ther. 9, 631 (2010)
Related Products
